Clinical Trial

Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Acute basilar artery occlusion is associated with high mortality and severe disability. Previous randomized trials have demonstrated the benefit of endovascular therapy in selected patients with basilar artery occlusion; however, patients with large ischemic core, commonly defined by low posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS), remain underrepresented and the benefit-risk profile of endovascular therapy in this subgroup is uncertain. This prospective, multicenter, randomized, open-label, blinded-endpoint trial will evaluate the efficacy and safety of endovascular therapy plus best medical management compared with best medical management alone in patients with acute basilar artery occlusion within 24 hours from symptom onset or last known well and pc-ASPECTS \<7. Eligible participants will be randomized in a 1:1 ratio to receive endovascular therapy plus best medical management or best medical management alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0 to 3 at 90 days.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-23.
Trial Details
NCT Number NCT07672795
Lead Sponsor The First Affiliated Hospital of University of Science and Technology of China
Collaborators: Dalian Municipal Central Hospital, Linyi People's Hospital, Fujian Zhangzhou hospital, Shanghai Minhang District Central Hospital
Conditions Acute Ischemic Stroke, Basilar Artery Occlusion, Large Ischemic Core
Enrollment 256 participants
Start Date 2026-08-01
Primary Completion 2029-07-30 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-02